LIN28A and acute myeloid leukemia: Our preliminary analysis revealed that the expression of LIN28A was dramatically increased in R-AML patients when compared with primary AML patients (p < 0.05, Figure 5C), which means patients with high expression of LIN28A are more likely to relapse.